Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from PYC Therapeutics Limited ( (AU:PYC) ).
PYC Therapeutics Limited has disclosed a change in director Peter Coleman’s interests, reporting the issue of 2,000,000 unlisted options as part of his remuneration. The options, granted pursuant to his letter of appointment, carry an exercise price of $1.80 and expire on 19 November 2028, marking Coleman’s first holding of these securities and signalling the company’s use of equity-based incentives to align director compensation with shareholder value.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-listed biotechnology company focused on developing therapeutic products, with its securities traded on the ASX. The company operates under Australian corporate and securities regulation, with directors’ holdings and changes in interests disclosed in accordance with ASX listing rules and the Corporations Act.
Average Trading Volume: 476,660
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$874.9M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.